Novel cytokine-based therapies and methods
AssigneeReverb Therapeutics, Inc.
InventorsDavid DE GRAAF, Mark FOGG, Surjit Bhimarao DIXIT, Stacey TOM-YEW
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods for redirecting an active form of an endogenous cytokine to a target cell or target tissue of interest in a biological system or subject in need thereof by administering a multi-specific binding molecule comprising (a) a binding domain that specifically binds to an active form of a cytokine and (b) a binding domain that specifically binds to an epitope on a molecule that is a marker on a target cell or tissue, wherein the multi-specific binding molecule, when bound to the cytokine, does not block or only partially blocks, the ability of the cytokine to bind to and agonize a cognate receptor for the cytokine.
Claims15
A method of redirecting an active form of a cytokine to a target cell or a target tissue of interest using a bispecific binding molecule, the method comprising:
- contacting a cell or a tissue of interest with a bispecific binding molecule, wherein the bispecific binding molecule comprises a cytokine binding domain that binds to a cytokine and a target-binding domain that binds to a target molecule, wherein the target molecule is a marker on the target cell in the target tissue, and wherein when a cytokine is complexed with the cytokine-binding domain the cytokine retains its ability to bind and/or agonize it cognate receptor compared to the ability of an unbound cytokine to bind to and/or agonize its cognate receptor as determined in an in vitro assay.
A method of redirecting an endogenous active form of a cytokine to a target cell or a target tissue of interest in a subject, the method comprising:
- administering to the subject a bispecific binding molecule comprising at least one cytokine-binding domain that binds to the cytokine and at least one target-binding domain that binds to a target molecule, wherein the target molecule is a marker on the target cell or the target tissue of interest,
- wherein the bispecific binding molecule has been identified in an in vitro cell-based assay from a plurality of bispecific binding molecules as permitting the cytokine, when complexed with the at least one cytokine-binding domain, to bind to and/or agonize its cognate receptor compared to an unbound cytokine, and wherein administering the bispecific binding molecule redirects the endogenous active form of the cytokine to the target cell or the target tissue of interest in the subject.
Dependencies are inferred from the claim text.